Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Firms Pursue “Select And Focus” Strategy To Accelerate R&D

Executive Summary

South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.

You may also be interested in...



Helixmith Plunges On Warning Of Possible Offering Delay

Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.

Asia Deal Watch: Bone Therapeutics Licenses Bone Cell Therapy Tech To Two Asian Firms

Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.

CrystalGenomics Eyes COVID-19 Trials As Hopes Rise For Ivaltinostat

Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel